The US Food and Drug Administration (FDA) has approved Avacta’s Investigational New Drug (IND) application for AVA6000, which will allow the group to expand its Phase I clinical trial, ALS-6000-101, into clinical trial sites in the United States. What is AVA6000? AVA6000 is a novel form of doxorubicin that has been modified with Avacta’s pre|CISION platform to improve its safety […]
Menu ≡ ╳ 
